MXCT
MaxCyte Hits High Notes in Challenging 2025 with Groundbreaking Launch of ExPERT DTx
MaxCyte, a leading biotechnology company, has made significant strides in a year marked by operational headwinds. Despite the challenges, the company demonstrated resilience and innovation, as highlighted during its recent Q4 2025 earnings call. According to Maher Masoud, President and Chief Executive Officer of MaxCyte, the company navigated the complex